Related Experiment Videos
Survival following hepatic transplantation in the cyclosporine era
Insights
Hepatic transplant survival reached 76% at six months. Advanced liver failure patients faced higher mortality, primarily due to technical errors, not infection or rejection, in the cyclosporine era.
Area of Science:
- Hepatology
- Transplant Surgery
- Immunosuppression
Background:
- Hepatic transplantation is a life-saving procedure for end-stage liver disease.
- Outcomes are influenced by patient condition and post-operative management.
- The introduction of new immunosuppressive agents has changed management protocols.
Purpose of the Study:
- To evaluate the outcomes of hepatic transplantation in a consecutive patient series.
- To identify factors influencing post-transplant survival.
- To analyze the causes of mortality following hepatic transplantation.
Main Methods:
- Retrospective analysis of 50 consecutive patients undergoing 55 hepatic transplants.
- Comparison of survival rates between patients with and without pre-transplant complications.
- Analysis of causes of death, including technical errors, rejection, and infection.
Main Results:
- Six-month survival rate was 76% for all hepatic transplant patients.
- Mortality was significantly higher in patients with advanced liver failure (56%) compared to others (10%).
- Primary causes of death were technical errors, with rejection and infection being uncommon.
Conclusions:
- The cyclosporine era has shifted mortality causes in hepatic transplantation.
- Improved immunosuppression and graft monitoring reduce reliance on corticosteroids, enhancing healing and infection resistance.
- Careful patient selection and surgical technique remain critical for successful hepatic allografts.
Abstract:
In a series of 50 consecutive patients receiving 55 hepatic transplants, the 6-month survival was 76 per cent. Mortality was considerably higher in patients with complications of advanced liver failure (56%) than in patients that were not hospital-confined preceding the transplant procedure (10%). The causes of death were related primarily to technical errors, and uncommonly caused by rejection or uncontrollable infection. This striking change in the cause of death occurring in the cyclosporine era results from the use of more specific immunosuppression and close scrutiny of the allograft with frequent hepatic biopsy. Both of these principles diminish the reliance on high-dose corticosteroid therapy, and therefore promote wound healing and resistance to fatal infection.